233 related articles for article (PubMed ID: 22535331)
21. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
Kay S; Ferreira A
Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
[TBL] [Abstract][Full Text] [Related]
22. The impact of age-related macular degeneration on health status utility values.
Espallargues M; Czoski-Murray CJ; Bansback NJ; Carlton J; Lewis GM; Hughes LA; Brand CS; Brazier JE
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4016-23. PubMed ID: 16249475
[TBL] [Abstract][Full Text] [Related]
23. Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration.
Revicki DA; Rentz AM; Harnam N; Thomas VS; Lanzetta P
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):712-7. PubMed ID: 19797233
[TBL] [Abstract][Full Text] [Related]
24. Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment.
Mueller S; Agostini H; Ehlken C; Bauer-Steinhusen U; Hasanbasic Z; Wilke T
Ophthalmology; 2016 Apr; 123(4):876-83. PubMed ID: 26778346
[TBL] [Abstract][Full Text] [Related]
25. Treatment and vision-related quality of life in the early manifest glaucoma trial.
Hyman LG; Komaroff E; Heijl A; Bengtsson B; Leske MC;
Ophthalmology; 2005 Sep; 112(9):1505-13. PubMed ID: 16019074
[TBL] [Abstract][Full Text] [Related]
26. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
27. Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study.
Oshima Y; Ishibashi Y; Umeda N; Nagata T; Yoshida S; Uchio E; Kondo H; Sonoda KH; Ishibashi T
BMC Ophthalmol; 2021 Jan; 21(1):58. PubMed ID: 33485320
[TBL] [Abstract][Full Text] [Related]
28. 24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes.
Canton VM; Quiroz-Mercado H; Velez-Montoya R; Lopez-Miranda MJ; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Ophthalmic Surg Lasers Imaging; 2012; 43(1):20-4. PubMed ID: 22251841
[TBL] [Abstract][Full Text] [Related]
29. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration.
Finger RP; Wickremasinghe SS; Baird PN; Guymer RH
Surv Ophthalmol; 2014; 59(1):1-18. PubMed ID: 24332379
[TBL] [Abstract][Full Text] [Related]
30. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT).
Maguire M;
Ophthalmology; 2004 Jul; 111(7):1307-16. PubMed ID: 15234130
[TBL] [Abstract][Full Text] [Related]
31. Patient and public preferences for health states associated with AMD.
Butt T; Dunbar HM; Morris S; Orr S; Rubin GS
Optom Vis Sci; 2013 Aug; 90(8):855-60. PubMed ID: 23811607
[TBL] [Abstract][Full Text] [Related]
32. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4.
Dong LM; Childs AL; Mangione CM; Bass EB; Bressler NM; Hawkins BS; Marsh MJ; Miskala P; Jaffee HA; McCaffrey LA;
Am J Ophthalmol; 2004 Jul; 138(1):91-108. PubMed ID: 15234287
[TBL] [Abstract][Full Text] [Related]
33. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
Dugel PU; Petrarca R; Bennett M; Barak A; Weinberger D; Nau J; Jackson TL
Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
35. Utility values in patients with acquired anophthalmus.
Hirneiss C; Neubauer AS; Herold TR; Kampik A; Hintschich C
Orbit; 2009; 28(6):332-6. PubMed ID: 19929654
[TBL] [Abstract][Full Text] [Related]
36. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L
Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121
[TBL] [Abstract][Full Text] [Related]
37. Effect of vitrectomy for epiretinal membrane on visual function and vision-related quality of life.
Okamoto F; Okamoto Y; Hiraoka T; Oshika T
Am J Ophthalmol; 2009 May; 147(5):869-74, 874.e1. PubMed ID: 19200531
[TBL] [Abstract][Full Text] [Related]
38. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
39. A new epidemiological aid in deciding whether to continue or stop a treatment.
Elshout M; van der Reis MI; Webers CA; La Heij EC; Hendrikse F; Schouten JS
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4331-6. PubMed ID: 22661474
[TBL] [Abstract][Full Text] [Related]
40. Vision-related quality of life in patients with bilateral severe age-related macular degeneration.
Cahill MT; Banks AD; Stinnett SS; Toth CA
Ophthalmology; 2005 Jan; 112(1):152-8. PubMed ID: 15629836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
